This study was designed to determine the maximum tolerated dose (MTD) of high-dose melphalan (HDM), with peripheral blood stem cell support, that could be given twice within 90 days to patients with multiple myeloma. The Intergroupe Français du Myelome (IFM) demonstrated superiority in response, overall survival (OS) and eventfree survival (EFS) following high-dose chemotherapy (HDC) and total body irradiation (TBI) with bone marrow (BM) support for patients with newly diagnosed multiple myeloma under the age of 65, compared to conventionaldose chemotherapy.
The Intergroupe Français du Myelome (IFM) demonstrated superiority in response, overall survival (OS) and eventfree survival (EFS) following high-dose chemotherapy (HDC) and total body irradiation (TBI) with bone marrow (BM) support for patients with newly diagnosed multiple myeloma under the age of 65, compared to conventionaldose chemotherapy. 1 Complete remissions (CR) were achieved in 5% of conventionally treated patients and 22% of patients receiving autologous BM transplants. 1 A recent 6 year follow-up shows a 21% survival for the conventional group compared to 43% for the transplant group (P = 0.03). 2 Correspondence: Dr CD Buckner, Response Oncology, Inc., 600 Broadway, Suite 112, Seattle, WA 98122, USA Received 2 January 1998; accepted 13 March 1998 Although cures following autologous stem transplantation have not been documented it is clear that this strategy improves the CR rate and prolongs survival. 1, 2 Since it is unlikely that patients who do not achieve CR will have prolonged EFS [3] [4] [5] [6] [7] [8] [9] [10] [11] attempts to improve CR rates with HDC are reasonable. In order to improve CR rates in patients with multiple myeloma tandem high-dose regimens have been explored. 12 When considering tandem or sequential high-dose treatments it is generally thought to be important to deliver such therapy within a short period of time. 13 Previous studies have demonstrated the feasibility of administering two cycles of HDM at 200 mg/m 2 but the minimum time interval between doses supported by PBSC has not been established. 12 The purpose of the current study was to determine the maximum tolerated doses (MTD) of HDM supported by peripheral blood stem cells (PBSC) that could be given within 90 days and to evaluate the effect of this strategy on response rates, especially in patients who had only received initial induction chemotherapy.
Patients and methods
Between March 1994 and 15 September 1995, 78 patients with multiple myeloma were entered on a phase I/II study evaluating two cycles of HDM with PBSC support (Tables  1 and 2 ). All patients met Durie and Salmon criteria for initial diagnosis of multiple myeloma, 14 were Ͻ66 years of age, had an ECOG performance status of 0-1 and had adequate renal, hepatic and cardiac function. All patients signed a protocol-specific informed consent form approved by the institutional review board of the hospital where the treatment was administered.
Treatment centers
Patients were treated in one of 28 participating medical centers in the United States under the care of 55 community oncologists affiliated with the Clinical Trials Division of Response Oncology Inc. (ROI) Memphis, TN, listed at the end of this manuscript. Chemotherapy for all three phases of treatment was administered and PBSC were harvested and infused in an outpatient facility. 15 Patients were admitted to hospitals meeting the criteria of ASCO/ASH guidelines for stem cell transplantation. 16 Induction chemotherapy Table 1 summarizes induction and reinduction chemotherapy regimens for these 78 patients. Seventy-two percent of patients received vincristine, doxorubicin and dexamethasone (VAD) induction, 13% received melphalan and prednisolone (MP) and 15% received other regimens.
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Mobilization of PBSC
Patients received cyclophosphamide 4 g/m 2 on day 1, etoposide 200 mg/m 2 on days 1-3 (CE) and granulocyte colony-stimulating factor (G-CSF), 6 g/kg/day (filgrastim, Amgen, Thousand Oaks, CA, USA) from day 4 until the completion of apheresis. Supportive care and grading of toxicities have been previously described. 15, 17 Collection, cryopreservation and infusion of PBSC Following the administration of CE and G-CSF, PBSC were harvested and cryopreserved as previously described. 18, 19 Peripheral blood stem cells were thawed rapidly and infused 48 h after the infusion of melphalan. 18, 19 The day of PBSC infusion was designated day 0. Measurement of CD34 + cells has been previously described. 19 
Study design
The first objective of this trial was to determine the MTD of HDM that could be administered sequentially within 42-90 days to Ͼ80% of patients with acceptable regimenrelated toxicities (RRT . Melphalan was administered to successive cohorts of four patients in both cycles of treatment, starting at level 1. After four patients were evaluated, dose escalation was allowed if no patient experienced RRT. If one of four patients in a cohort experienced severe RRT, another cohort of four patients received the same dose and if 1/4 of this cohort had severe RRT (total of 2/8) this was considered to be the probable MTD. If 3/8 developed severe RRT or 2/8 had toxic deaths the next patients were entered at the lower dose level. Only three patients were treated simultaneously at an untested dose level. Patients enrolled on study while observations were pending on previously treated patients were entered at the next lower dose level.
The administration of cycle 2 of HDM occurred Ͼ42 days after cycle 1 when patients had resolution of all grade 4 non-hematologic toxicity, had an ANC Ͼ1.5 ϫ 10 9 /l, were no longer receiving platelet transfusions, were afebrile and not receiving antibiotics and were ambulatory with adequate oral intake.
Phase II: The objectives of the phase II part of the study were to confirm toxicities estimated in the phase I study and to determine response rate, OS and EFS following sequential HDM administered at the MTD.
Toxicity and engraftment definitions
All patients were evaluated daily until resolution of symptoms and were graded for toxicities using common criteria. 17 Neutrophil engraftment was defined as the first of 2 consecutive days on which the ANC exceeded 0.5 ϫ 10 9 /l following the nadir. Platelet engraftment was defined as the first of 7 consecutive days on which the platelet count exceeded 20.0 ϫ 10 9 /l without transfusions.
Evaluation of response
Patients were staged within 14 days of beginning mobilization chemotherapy, within 10 days of cycle 1 of HDM, within 10 days of cycle 2 of HDM and 60 days after completing cycle 2 of HDM. Staging studies included: BM examination, skeletal survey with supplemental magnetic resonance imaging when indicated, serum and 24-h urine testing by protein electrophoresis, immunofixation and ␤ 2 -microglobulin determination. Response definitions: Criteria for CR included normal BM cellularity with Ͻ5% plasma cells, no monoclonal protein detected in serum or urine by immunofixation and absence of progression of bone disease on two evaluations at least 3 months apart. A very good partial response (VGPR) was defined as a decrease у75% in the monoclonal protein level and a BM examination with р5% plasma cells on two tests at least 1 month apart. Partial response (PR) was defined as у50% and р75% reduction in monoclonal protein on two tests at least a month apart. Unresponsive disease was failure to achieve у50% reduction in serum or urine monoclonal protein.
Resistant disease was у25% increase in serum or urine monoclonal protein.
Classification of disease status: Primary responsive disease was уPR following initial therapy, primary unresponsive was failure to achieve a PR or CR with primary therapy, primary resistance was disease progression as determined by у25% increase in monoclonal protein following induction therapy, responsive relapse was уPR following reinduction therapy, unresponsive relapse was рPR following reinduction chemotherapy and resistant relapse was relapse from an initial remission with subsequent disease progression as evidenced by у25% increase in monoclonal protein following reinduction therapy.
Statistics
All data were collected using a custom-designed distributed data system, reviewed at a central clinical trials center (ROI) and analyzed using the SAS system (SAS Institute, Cary, NC, USA). Proportions were compared using 2 or Fisher's exact method, as appropriate. Differences between groups in continuous variables were tested using the Wilcoxon rank sum test. Neutrophil and platelet recovery rates, OS, EFS and probability of relapse or progression were estimated using the product-limit method according to Kaplan and Meier and compared using the log-rank test. 20 Survival and time to relapse or progression of disease were calculated from the date of starting mobilizing chemotherapy until the date of last contact, with the date of latest follow-up being 21 November 1997.
Results
Patient characteristics (Table 1)
Characteristics of the 78 patients are shown in Table 1 .
Protocol compliance
All 78 patients completed induction or re-induction chemotherapy and mobilization of PBSC. Three patients were removed from study after mobilization of PBSC because insufficient CD34
+ cells were harvested to support one cycle of HDM (n = 2) or because of toxicity from vincristine (n = 1). Seventy-five patients (96%) received the first cycle and 58 (74%) completed a second cycle of HDM on either the phase I or phase II parts of this study.
Results of mobilization of PBSC (Table 2)
CD34
+ cell yields for all 78 patients are shown in Table 2 .
Phase I dose escalation study
None of four patients enrolled at dose level 1 (160 mg/m 2 ) had dose-limiting toxicity. One of four patients in the first cohort at dose level 2 (180 mg/m 2 ) had a delay to day 99 in receiving cycle 2 but did not have unresolved grade 4 RRT. This same patient had severe RRT and died of Pneumocystis carinii pneumonia 18 days after cycle 2 with recovery of neutrophils but not platelets. In the second cohort at dose level 2 (180 mg/m 2 ) no patient had severe RRT, resulting in dose-limiting RRT in 1/8 patients treated at this dose level. At dose level 3, one patient in cohort 1 had a delay to day 99 in administering cycle 2 and no patient had severe RRT after receiving cycle 2. In the second cohort at dose level 3, one patient developed doselimiting RRT, had repeated episodes of infection associated with steroid dependence and ultimately died of myocardial infarction 5 months after cycle 1 of HDM. Dose level 3 (200 mg/m 2 ) was estimated to be the probable MTD because two of eight patients developed dose-limiting RRT.
Eight patients were treated at dose level one (n = 2) or dose level 2 (n = 6) pending observation of patients treated at higher dose levels. These eight patients were included in evaluations of engraftment, response and overall outcome but were not included in analysis of the dose-escalation trial.
Phase II evaluation of two cycles of melphalan at 200 mg/m 2
Toxicities associated with cycle 1: Fifty-five patients received 200 mg/m 2 of melphalan in cycle 1, eight were enrolled in the phase I dose escalation study and 47 in the phase II study. One patient (2%) developed severe RRT and did not proceed to the second cycle. Two patients died (4%); one 14 days after PBSC infusion of infection and multi-organ failure without engraftment of neutrophils or platelets, and one on day 83 of disseminated herpes zoster infection.
Failure to receive cycle 2:
Seventeen patients (31%) did not receive cycle 2 of HDM; six for non-medical reasons and 11 for medical reasons. Non-medical reasons included insurance denial (n = 3) and patient refusal (n = 3). Medical reasons for 11 patients not receiving cycle 2 of HDM included treatment-related deaths (n = 2), physician withdrawal from study (n = 2), severe RRT after cycle (n = 1) and low CD34 + cell harvests (n = 6). The latter six patients had a median of 2.7 ϫ 10 6 CD34 + cells/kg harvested (range 1.4-4.5) and did not proceed to the second cycle of HDM as all PBSC were infused after cycle 1 of HDM.
Delay in receiving cycle 2:
Eight of 38 patients (21%) received cycle 2 of HDM later than the goal of 90 days, at a median of 99 days (range 91-225) following the first cycle. Reasons for delay in administering the second cycle of HDM included administrative delay (n = 3), bacterial infection (n = 3), gastrointestinal toxicity (n = 1) and thrombocytopenic purpura (n = 1).
Toxicities associated with cycle 2:
Thirty-eight patients received a second cycle of HDM a median of 70 days (range 41-225) following the first cycle. One patient (3%) died of bacterial infection with disseminated intravascular coagulation at 45 days with recovery of neutrophils and platelets and there were no patients with unresolved grade 4 RRT.
Duration of treatment for non-salvage patients (Table 3)
Times of treatment from initial induction for 62 nonsalvage patients are shown in Table 3 . Table 3 Time of treatment from initial induction chemotherapy in non-salvage patients (n = 62) 
Evaluation of engraftment in all patients (Table 4)
Seventy-five patients were evaluable for engraftment following one or two cycles of HDM on the phase I or phase II study and the results are shown in Table 4 .
Resource utilization following sequential treatment (Table  5 ) Table 5 shows the resource utilization patterns for each phase of treatment, except induction chemotherapy.
Outcomes for all 78 patients
Clinical response (Table 6) : Four of 78 patients were not evaluable for response following all phases of treatment; one achieved a PR on induction and was lost to follow-up after the first cycle of HDM, one had stable disease after the first cycle of HDM but was lost to follow-up after the second cycle and two patients died early after the second cycle of HDM. Responses to sequential treatment in evaluable patients are shown in Table 6 . Four of 17 patients (23%) who only received one cycle of HDM were in CR when initially restaged. However, two additional patients were in CR on subsequent staging, with an overall CR rate of 6/17 (35%) for patients receiving only one cycle of HDM. Seven of 58 patients (12%) who ultimately received two cycles of HDM were in CR after cycle 1.
Twenty-eight of 62 patients (45%) who had only received induction therapy achieved a CR compared to 9/16 patients (56%) who received salvage therapy after failing initial chemotherapy.
Complete remissions were achieved in 61% of 33 patients with primary responsive disease (n = 31) or responsive relapse (n = 2) compared to 36% of 45 patients with primary unresponsive disease (n = 31) or unresponsive relapse (n = 14) (P = 0.03).
OS, EFS and relapse/progression: Sixty-three of 78 patients (81%) are alive, 56 (72%) without disease progression at a median of 20 months (range 9-39). The probabilities of OS, EFS and relapse or progression at 18 months for all 78 patients entered on study were 0.87, 0.75 and 0.20, respectively.
The probabilities of OS and EFS for the 62 patients who had only received induction chemotherapy were 0.88 and 0.77, respectively. The probabilities of OS and EFS for the 16 patients who had failed prior chemotherapy were 0.81 and 0.69, respectively.
The probabilities of OS and EFS for the 33 patients with primary responsive disease (n = 31) or responsive relapse (n = 2) were 0.92 and 0.89, respectively, compared to 0.82 (P = 0.7) and 0.66 (P = 0.07), respectively, for 45 patients with primary unresonsive disease (n = 31) or unresponsive relapse (n = 14).
The probabilities of relapse or progression for the 36 patients achieving a CR and for the 42 patients achieving ϽCR were 0.18 and 0.23, respectively (P = 0.72). The probabilities of relapse or progression for the 59 patients achieving CR or VGPR and for the 19 patients achieving ϽVGPR were 0.17 and 0.35, respectively (P = 0.07). occurring 18 days after cycle 2 of HDM in a patient who had had severe RRT following cycle 1.
In the phase II trial, 17 of 55 patients (31%) did not receive the second cycle of HDM. However, only three of the 17 patients had severe medical problems precluding the administration of the second cycle of HDM, including two treatment-related deaths and one grade 4 RRT. For 49 newly diagnosed patients, the entire sequence of treatment including induction, was accomplished in a median of 8 months (range 5.6-15.6) with a median hospitalization time of 23 days (range 0-62) for mobilization and two cycles of HDM.
The CR rate for the entire population of 78 patients was 46%. Eleven of 74 evaluable patients (15%) were in CR following cycle 1 of HDM and 30 of 55 (55%) after cycle 2. The improvement in CR rate from 15 to 55% is probably an overestimate of the benefits of a second cycle of HDM. In the 17 patients who received only one cycle of melphalan, the ultimate CR rate was 35%. The lower response rate following cycle one in patients receiving two cycles of HDM is undoubtedly due to early restaging which precludes definitive analysis as median times to maximum response can be 3-6 months. 21 The transplant group at the University of Arkansas pioneered the use of tandem autografts with HDM with and without TBI for patients with multiple myeloma. 12 In their initial studies utilizing BM, attempts were made to deliver two cycles of high-dose therapy within 6 months and 80% were able to receive a planned second transplant within 1 year. Tandem transplants increased the CR rate from 24 to 43%. 12 Using a landmark analysis for 440 patients surviving 6 months after the first transplant, an early first transplant (р12 months of standard therapy) and timely administration of the second transplant (р6 months from the first transplant) were associated with superior EFS (44 vs 23 months, P = 0.0001) and OS (66+ vs 40 months, P = 0.0003), respectively. 12 A recent report of double autotransplants, utilizing BM or PBSC, in 15 patients with limited prior treatment showed that 11 (73%) were able to receive a melphalan and TBI regimen after melphalan 200 mg/m 2 for the first transplant. The interval between transplants was a median of 2.8 months (range 1.8-6.5) and the median time from diagnosis to first transplant was 7.5 months (range 4.4-29.5) with a CR rate of 60%. 22 However, The IFM performed a large randomized trial comparing melphalan 140 mg/m 2 and TBI (8 Gy) to double autologous transplants with melphalan 140 mg/m 2 followed by melphalan 140 mg/m 2 and TBI (8 Gy). CR rates were 33 and 32%, respectively, with no difference in EFS at 2 years. 23 These results differ significantly from reported phase II studies and the current study. 12, 22 The explanation for these differences is not clear but could be related to the sequence of therapy, the dose of melphalan or that maximal effect is achieved with a TBI-based regimen. A comparison of two cycles of HDM at 200 mg/m 2 to a single transplant with melphalan and TBI would be of interest.
In summary, induction, mobilization of PBSC and two cycles of HDM can be administered at a median of 8 months to approximately 70% of newly diagnosed patients with multiple myeloma under the age of 66, with a progressive increase in CR rate to approximately 50%. However, the ultimate differences between one and two cycles of HDM can probably not be defined without a randomized trial. The effects of tandem HDM on long-term EFS will require further follow-up.
